JCML clinical trials at UCSF

1 research study open to eligible people

JCML is a rare type of leukemia found in children. UCSF is testing a combination of trametinib and azacitidine to see if it is safe and effective for newly diagnosed patients. This trial is currently recruiting participants.

Showing trials for

  • Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    open to eligible people ages 1 month to 21 years

    This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

    San Francisco, California and other locations

Last updated: